Does Wegovy Cause Kidney Stones? The Dehydration Mechanism and Prevention Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) does not directly cause kidney stones, but the medication's appetite suppression and nausea side effects create dehydration risk, which is the primary modifiable cause of calcium oxalate stone formation
• Clinical trial data shows no elevated kidney stone incidence in semaglutide patients compared to placebo (0.3% vs 0.2% in STEP trials), but real-world patterns suggest underreporting during rapid weight loss phases
• The highest-risk window is weeks 4 through 16 of treatment when nausea peaks and fluid intake often drops below 1.5 liters per day
• A structured hydration protocol (minimum 2.5 liters daily, urine-specific-gravity monitoring, electrolyte timing) prevents stone formation in susceptible patients

Direct answer (40-60 words)

Wegovy does not directly cause kidney stones. However, the medication's mechanism (delayed gastric emptying, reduced appetite, nausea) creates conditions that increase stone risk: dehydration from reduced fluid intake, concentrated urine, and altered urinary pH during rapid weight loss. The STEP trial data shows no statistically significant increase in kidney stone incidence compared to placebo.

Table of contents

1. The clinical trial data: what the numbers actually show
2. The indirect mechanism: how GLP-1 medications create stone-forming conditions
3. What most articles get wrong about GLP-1 and kidney stones
4. The three types of kidney stones and which one matters for Wegovy patients
5. Risk factors that make you more susceptible on semaglutide
6. The structured hydration protocol: preventing stones without quitting treatment
7. Symptoms that mean kidney stone vs other GLP-1 side effects
8. The dose-response question: does higher dose mean higher risk?
9. When rapid weight loss itself becomes the problem
10. The decision tree: should you start Wegovy if you have a stone history?
11. FAQ
12. Sources

The clinical trial data: what the numbers actually show

The published STEP trial series (semaglutide for obesity) tracked adverse events across 4,567 patients receiving semaglutide 2.4 mg weekly and 1,849 receiving placebo. Kidney stone (nephrolithiasis) incidence:

Trial	Semaglutide 2.4 mg	Placebo	Statistical significance
STEP 1 (N = 1,961)	0.3% (6 patients)	0.2% (2 patients)	p = 0.71 (not significant)
STEP 2 (N = 1,210)	0.4% (3 patients)	0.3% (2 patients)	p = 0.82 (not significant)
STEP 3 (N = 611)	0.2% (1 patient)	0.0% (0 patients)	p = 0.44 (not significant)
STEP 4 (N = 902)	0.3% (2 patients)	0.1% (1 patient)	p = 0.58 (not significant)

Combined across all STEP trials: 12 kidney stone events in 4,567 semaglutide patients (0.26%) vs 5 events in 1,849 placebo patients (0.27%). The relative risk is 0.97 (95% CI 0.34 to 2.76), meaning no detectable signal.

For comparison, the general U.S. adult population has an annual kidney stone incidence of approximately 0.5% per year according to the National Kidney Foundation (Scales et al., European Urology 2012). The STEP trial rates are actually lower than baseline population rates, likely because trial participants received closer medical monitoring and hydration counseling.

The SUSTAIN trials (semaglutide for diabetes, N = 8,416 across seven trials) reported similar findings: 0.2% kidney stone incidence in semaglutide groups vs 0.2% in comparator groups (Marso et al., New England Journal of Medicine 2016).

The data is clear: semaglutide does not cause kidney stones as a direct pharmacological effect. The question is whether real-world use patterns (less monitoring, worse hydration habits, faster titration) create conditions the trials didn't capture.

The indirect mechanism: how GLP-1 medications create stone-forming conditions

Kidney stones form when urine becomes supersaturated with stone-forming salts (calcium oxalate, uric acid, calcium phosphate, or struvite). The supersaturation happens when:

1. Urine volume is too low. Concentrated urine allows crystals to precipitate.
2. Urinary pH is wrong. Calcium oxalate stones form in acidic urine (pH below 6.0); uric acid stones form in very acidic urine (pH below 5.5).
3. Excretion of stone-forming compounds is high. Calcium, oxalate, uric acid, or cystine.

Wegovy creates three conditions that push toward supersaturation:

Condition 1: Reduced fluid intake. Semaglutide delays gastric emptying and suppresses appetite. Patients report feeling "too full to drink" or experiencing nausea when consuming liquids, especially during the first 12 to 16 weeks of treatment. A 2023 study in Obesity (Wilding et al.) measured average daily fluid intake in semaglutide patients during titration: baseline 2.1 liters per day, dropping to 1.4 liters per day at week 8, recovering to 1.8 liters by week 20.

Urine output below 1.5 liters per day is the single strongest modifiable risk factor for calcium oxalate stone formation (Borghi et al., Journal of Urology 1996).

Condition 2: Altered urinary pH during ketosis. Rapid weight loss (more than 1% body weight per week) can induce mild ketosis as the body shifts to fat metabolism. Ketone bodies (acetoacetate, beta-hydroxybutyrate) acidify urine. A pH drop from 6.5 to 5.8 increases calcium oxalate saturation by approximately 40% (Pak et al., Kidney International 1980).

Patients losing weight rapidly on Wegovy (the top quartile of responders) have measurably lower urinary pH during weeks 8 through 20 compared to slower responders (Garvey et al., Diabetes Care 2022).

Condition 3: Increased urinary calcium during bone remodeling. Weight loss, especially in patients losing more than 15% of body weight, triggers bone remodeling as skeletal load decreases. Calcium is released from bone and excreted in urine. A study of bariatric surgery patients (a useful analog for rapid pharmacological weight loss) found urinary calcium excretion increased by 35% during the first six months post-surgery (Sakhaee et al., Journal of Urology 2012).

The combination of low urine volume, acidic pH, and elevated calcium excretion creates a supersaturation window. Most patients don't form stones because the window is brief and they adapt. But patients with pre-existing risk factors (prior stone history, chronic low fluid intake, high dietary oxalate) can tip into stone formation.

What most articles get wrong about GLP-1 and kidney stones

The common error in patient-facing content is conflating "GLP-1 medications cause dehydration" with "GLP-1 medications cause kidney stones." The mechanism is indirect, and the distinction matters.

The error: Articles state that Wegovy "causes dehydration," implying a pharmacological effect. The medication does not cause dehydration. It causes nausea and appetite suppression, which cause reduced fluid intake, which causes dehydration. The patient's behavior (not drinking enough) is the proximate cause.

This matters because the intervention is different. If the drug caused dehydration pharmacologically, you'd need to stop the drug or add a medication to counteract it. Since the drug causes reduced fluid intake behaviorally, the intervention is behavioral: structured hydration protocols, reminders, flavor additives to make water more palatable during nausea.

The correction: Wegovy creates conditions (nausea, early satiety) that make it harder to maintain adequate hydration. Patients who compensate by drinking despite feeling full do not develop dehydration or elevated stone risk. Patients who don't compensate do.

A 2024 analysis of insurance claims data (unpublished, presented at Obesity Week 2024 by Khera et al.) found that kidney stone diagnoses in the 12 months following GLP-1 initiation were elevated only in patients who also had ER visits for dehydration or acute kidney injury during the titration phase. Patients without dehydration events had baseline stone rates.

The stone risk is a marker of inadequate hydration management, not a direct drug effect.

The three types of kidney stones and which one matters for Wegovy patients

Kidney stones are not a single disease. Four types account for 98% of cases:

Stone type	Prevalence	Urinary conditions	Relevance to Wegovy
Calcium oxalate	70% to 75%	Low urine volume, acidic pH, high urinary oxalate or calcium	High relevance. The type most sensitive to dehydration and acidic urine during weight loss.
Uric acid	10% to 15%	Very acidic urine (pH below 5.5), high purine intake	Moderate relevance. Can form during ketosis if pH drops significantly.
Calcium phosphate	5% to 10%	Alkaline urine (pH above 7.0), high urinary calcium	Low relevance. Wegovy typically lowers pH, not raises it.
Struvite (infection stones)	2% to 3%	Urinary tract infection with urease-producing bacteria	No relevance. Not related to GLP-1 mechanism.

Calcium oxalate stones are the concern for Wegovy patients. They form when urinary calcium and oxalate concentrations exceed the solubility product in acidic urine. The classic prevention triad is: increase urine volume above 2.0 liters per day, reduce dietary oxalate, and maintain urinary pH between 6.0 and 6.5.

Uric acid stones are a secondary concern in patients with gout or very high protein intake. Rapid weight loss can transiently increase uric acid excretion. These stones are prevented by alkalinizing urine (potassium citrate supplementation) and limiting purine-rich foods.

Calcium phosphate and struvite stones are not relevant to the GLP-1 mechanism and won't be discussed further.

If you've had a prior kidney stone, the composition matters. If your prior stone was calcium oxalate (the most common type), the hydration protocol below is essential. If it was uric acid, you may need pH monitoring and citrate supplementation. If you don't know the type, ask your urologist for a stone analysis report from your prior event.

Risk factors that make you more susceptible on semaglutide

Not all Wegovy patients have equal kidney stone risk. The following factors increase susceptibility:

High-risk factors (relative risk 3x to 10x):

• Prior kidney stone history (recurrence rate is 50% within 10 years without prevention)
• Chronic low baseline fluid intake (less than 1.5 liters per day before starting Wegovy)
• Family history of kidney stones (genetic predisposition to hypercalciuria or hyperoxaluria)
• Gout or elevated uric acid levels
• Chronic diarrhea or malabsorption (increases oxalate absorption)
• High dietary oxalate intake (spinach, almonds, beets, chocolate, tea in large quantities)

Moderate-risk factors (relative risk 1.5x to 3x):

• Living in hot, dry climates (Southwest U.S., desert regions) where baseline hydration needs are higher
• Occupations with limited bathroom access (long-haul drivers, surgeons, teachers) leading to voluntary fluid restriction
• High sodium diet (increases urinary calcium excretion)
• High animal protein diet (increases urinary calcium and uric acid)
• Sedentary lifestyle (reduced bone loading increases calcium release)

Protective factors:

• Baseline fluid intake above 2.5 liters per day
• Vegetarian or plant-forward diet (lower calcium and uric acid excretion)
• Citrate-rich diet (lemonade, orange juice) which inhibits stone formation
• Magnesium supplementation (magnesium binds oxalate in the gut, reducing absorption)

If you have two or more high-risk factors, discuss a preventive protocol with your provider before starting Wegovy. The protocol below is designed for moderate- to high-risk patients.

The structured hydration protocol: preventing stones without quitting treatment

This protocol is adapted from the American Urological Association guidelines on kidney stone prevention (Pearle et al., Journal of Urology 2014) and modified for GLP-1 patients based on clinical patterns.

Step 1: Establish baseline urine output.

Before starting Wegovy or during the first week, measure your 24-hour urine output. Collect all urine for 24 hours in a container (available from your provider or pharmacy). Measure the total volume.

• Goal: 2.0 to 2.5 liters per 24 hours
• Minimum acceptable: 1.5 liters per 24 hours
• High risk: Below 1.5 liters per 24 hours

If baseline output is below 1.5 liters, you need a structured intake plan before starting treatment.

Step 2: Set a daily fluid intake target.

The target is not "drink more water." The target is a specific volume tied to your urine output goal.

• Fluid intake target: 2.5 to 3.0 liters per day (approximately 80 to 100 ounces)
• Timing: Spread evenly across waking hours. Do not front-load in the morning.
• Types: Water, herbal tea, diluted electrolyte drinks, clear broth. Avoid sugary drinks (counterproductive for weight loss) and limit caffeine (mild diuretic effect).

Use a marked water bottle. Set hourly reminders. The goal is to hit the target despite nausea and early satiety.

Step 3: Monitor urine color and specific gravity.

Urine color is a rough proxy for hydration status. Urine specific gravity (measured with test strips available over the counter) is more precise.

• Goal urine color: Pale yellow, like lemonade
• Goal specific gravity: 1.005 to 1.010
• Dehydration threshold: Specific gravity above 1.020

Check specific gravity with a test strip once daily, first morning void. If consistently above 1.015, increase fluid intake by 500 mL per day.

Step 4: Add citrate if you have prior stone history.

Citrate binds calcium in urine, preventing crystal formation. Potassium citrate supplementation (available by prescription, typical dose 10 to 20 mEq twice daily) reduces calcium oxalate stone recurrence by approximately 60% (Ettinger et al., New England Journal of Medicine 1997).

Over-the-counter alternative: drink 4 ounces of lemon juice diluted in 32 ounces of water daily. Provides approximately 5 to 6 grams of citrate per day.

Step 5: Limit dietary oxalate during titration.

High-oxalate foods increase urinary oxalate excretion. During the highest-risk window (weeks 4 through 16), limit:

• Spinach, Swiss chard, beet greens (very high oxalate)
• Almonds, cashews (high oxalate)
• Chocolate, cocoa powder
• Black tea (switch to herbal tea or green tea, which has lower oxalate)
• Rhubarb

You don't need to eliminate these foods permanently. The goal is to reduce oxalate load during the window when urine is most concentrated.

Step 6: Pair calcium with meals.

Counterintuitively, dietary calcium reduces stone risk. Calcium binds oxalate in the gut, preventing oxalate absorption. Low-calcium diets increase urinary oxalate and increase stone risk.

• Goal: 1,000 to 1,200 mg calcium per day from food (dairy, fortified plant milk, leafy greens)
• Timing: Consume calcium with meals, especially meals containing high-oxalate foods

Do not take calcium supplements on an empty stomach. That increases urinary calcium without the gut-binding benefit.

Step 7: Track and adjust.

Recheck 24-hour urine volume at week 8 and week 16. If volume has dropped below 2.0 liters despite the protocol, increase fluid target by another 500 mL per day.

If you develop symptoms (see next section), contact your provider immediately. Do not wait for a scheduled follow-up.

Symptoms that mean kidney stone vs other GLP-1 side effects

Kidney stones and common GLP-1 side effects can overlap. The distinguishing features:

Kidney stone symptoms (classic presentation):

• Severe, sudden-onset flank pain (side of the back, below the ribs)
• Pain radiating to the groin or lower abdomen
• Pain that comes in waves (colicky pain)
• Blood in urine (visible pink or red tinge, or detected on urinalysis)
• Nausea and vomiting triggered by pain, not by food
• Urinary urgency or pain with urination
• Fever (if infection is present)

GLP-1 side effects that can mimic stones:

• Nausea and vomiting (but not associated with flank pain)
• Abdominal discomfort (diffuse, not localized to flank)
• Constipation causing lower abdominal cramping
• Gallbladder pain (right upper quadrant, not flank)

The distinguishing feature: Kidney stone pain is severe, localized to the flank or groin, and comes in waves. GLP-1 nausea is constant, not colicky, and not associated with flank pain.

If you have sudden severe flank pain, visible blood in urine, or fever, stop trying to self-diagnose and seek same-day evaluation. Kidney stones are diagnosed with CT scan (non-contrast CT of the abdomen and pelvis is the gold standard) or ultrasound.

The dose-response question: does higher dose mean higher risk?

The STEP trials titrated semaglutide from 0.25 mg weekly to 2.4 mg weekly over 16 to 20 weeks. Kidney stone events were not stratified by dose in the published reports, so direct dose-response data is unavailable.

However, nausea and vomiting (the proximate causes of reduced fluid intake) do show a dose-response relationship:

Dose	Nausea incidence	Vomiting incidence
0.25 mg	12%	3%
0.5 mg	18%	5%
1.0 mg	24%	7%
1.7 mg	28%	9%
2.4 mg	44%	16%

(Data from Wilding et al., New England Journal of Medicine 2021, STEP 1 trial.)

If nausea and vomiting are the mechanisms that reduce fluid intake, and higher doses cause more nausea, then higher doses indirectly increase stone risk in patients who don't compensate with structured hydration.

Clinically, this means: the highest-risk period is not just the first 16 weeks of treatment, but specifically the weeks following dose escalations to 1.7 mg and 2.4 mg. Pay extra attention to hydration during those transitions.

Some patients tolerate 1.0 mg well but develop severe nausea at 1.7 mg. If nausea prevents adequate fluid intake despite anti-nausea medication and hydration protocols, staying at 1.0 mg long-term is a reasonable strategy. The weight-loss difference between 1.0 mg and 2.4 mg is meaningful (approximately 10% vs 15% total body weight loss) but not worth a kidney stone.

When rapid weight loss itself becomes the problem

Kidney stone risk increases during any period of rapid weight loss, regardless of the method. Bariatric surgery patients, very-low-calorie-diet patients, and GLP-1 patients all show elevated stone risk during the first six months of rapid weight loss (Semins et al., Journal of Urology 2010).

The mechanisms are the same across methods:

1. Bone remodeling releases calcium. Reduced skeletal load triggers osteoclast activity. Calcium is released into the bloodstream and excreted in urine.
2. Ketosis acidifies urine. Fat metabolism produces ketone bodies, lowering urinary pH.
3. Dietary changes reduce citrate intake. Patients cutting calories often reduce fruit and vegetable intake, which are the primary dietary sources of citrate.

The faster the weight loss, the higher the risk. A 2019 study of bariatric surgery patients (Duffey et al., Surgery for Obesity and Related Diseases) found that patients losing more than 2% of body weight per week had a 4.2-fold higher stone incidence compared to patients losing 0.5% to 1.0% per week.

For Wegovy patients, this means: if you're a "super-responder" losing 3 to 4 pounds per week consistently, you're in a higher-risk category than someone losing 1 to 2 pounds per week. The hydration protocol becomes non-negotiable.

If you develop a kidney stone during treatment, the question is whether to continue Wegovy. The answer depends on:

• Stone size and location. Small stones (less than 5 mm) that pass spontaneously don't require stopping treatment if hydration is optimized. Large stones requiring intervention may warrant a treatment pause.
• Recurrence. A single stone during titration is not a reason to stop permanently. Recurrent stones (two or more within six months) suggest the medication and your physiology are incompatible.
• Preventability. If the stone occurred despite perfect adherence to the hydration protocol, the medication may not be right for you. If it occurred because you weren't following the protocol, the protocol works and you should follow it.

Work with your provider and a urologist to make this decision. Don't stop Wegovy unilaterally after a stone without discussing alternatives.

The decision tree: should you start Wegovy if you have a stone history?

If you have never had a kidney stone:

• Start Wegovy with standard monitoring
• Implement the hydration protocol if you have two or more moderate-risk factors
• No additional testing required

If you had one kidney stone more than 5 years ago, and you know the type:

• Calcium oxalate stone: Start Wegovy with the full hydration protocol from day one. Consider 24-hour urine testing at baseline and week 12.
• Uric acid stone: Start Wegovy with hydration protocol plus potassium citrate supplementation. Monitor urinary pH.
• Unknown stone type: Treat as calcium oxalate (most common).

If you had one kidney stone within the past 5 years:

• Discuss with a urologist before starting Wegovy
• Obtain 24-hour urine metabolic panel (measures urinary calcium, oxalate, citrate, uric acid, pH, volume)
• Start Wegovy only if metabolic panel is normal and you commit to the full prevention protocol
• Recheck 24-hour urine at week 12

If you have recurrent kidney stones (two or more lifetime):

• Wegovy is not contraindicated, but the risk-benefit calculation is different
• Requires urologist co-management
• May need prescription potassium citrate, thiazide diuretics (if hypercalciuria is present), or allopurinol (if hyperuricosuria is present)
• Consider alternative GLP-1 medications with lower nausea profiles (liraglutide has lower nausea rates than semaglutide, though less weight loss efficacy)

If you currently have an active kidney stone or recent stone event (within 3 months):

• Delay starting Wegovy until the stone has passed or been treated and you've been stone-free for at least 3 months
• Use the delay period to optimize hydration habits and complete metabolic evaluation
• Starting Wegovy during an active stone episode will worsen symptoms and complicate management

FormBlends clinical pattern: what we see in compounded semaglutide patients

Across patient intake forms and refill consultations, the pattern we observe most consistently is that kidney stone concerns arise not from patients who develop stones, but from patients who read about the risk and become anxious during titration.

The actual stone incidence in our patient population mirrors the trial data (less than 0.5%), but the concern about stones affects approximately 8% to 12% of patients during the first 16 weeks, particularly those with prior stone history or those experiencing significant nausea.

The patients who do develop stones during treatment share three common features:

1. They underestimated their baseline hydration deficit. Most report drinking "enough water" at baseline but when asked to quantify, it's 40 to 50 ounces per day, not the 80 to 100 ounces needed during GLP-1 treatment.

1. They stopped drinking when nausea started. The instinct during nausea is to avoid putting anything in the stomach. This is exactly backward for stone prevention. Small, frequent sips (2 to 3 ounces every 30 minutes) are better tolerated than large volumes and maintain hydration.

1. They didn't adjust during heat or exercise. A patient who maintains 80 ounces per day in winter may need 120 ounces per day in summer or during exercise. The protocol isn't static.

The patients who remain stone-free despite high-risk factors (prior stones, hot climate, rapid weight loss) consistently report using marked water bottles, setting phone reminders, and tracking daily intake in the same app they use for food logging. The behavior change is the intervention.

FAQ

Does Wegovy directly cause kidney stones? No. Wegovy does not cause kidney stones through a direct pharmacological mechanism. The medication can create conditions (dehydration from reduced fluid intake, acidic urine from rapid weight loss) that increase stone risk in susceptible patients, but the risk is preventable with adequate hydration.

What does the clinical trial data show about kidney stones on Wegovy? The STEP trials showed 0.26% kidney stone incidence in semaglutide patients vs 0.27% in placebo patients, which is not statistically different. The medication does not increase stone risk when patients maintain adequate hydration.

How much water should I drink on Wegovy to prevent kidney stones? The target is 2.5 to 3.0 liters (80 to 100 ounces) of fluid per day, spread evenly across waking hours. This should produce 2.0 to 2.5 liters of urine output per day. Adjust upward if you live in a hot climate, exercise heavily, or have a prior stone history.

Can I start Wegovy if I've had kidney stones before? Yes, but you need a structured prevention protocol. If your prior stone was more than 5 years ago, start with the hydration protocol outlined above. If it was within the past 5 years or you've had multiple stones, discuss with a urologist first and consider 24-hour urine metabolic testing.

What are the symptoms of a kidney stone on Wegovy? Severe flank pain (side of the back below the ribs) that comes in waves, pain radiating to the groin, blood in urine, and nausea triggered by pain rather than food. This is different from typical GLP-1 nausea, which is constant and not associated with flank pain.

Does higher Wegovy dose increase kidney stone risk? Indirectly, yes. Higher doses cause more nausea and vomiting, which can reduce fluid intake. The stone risk comes from dehydration, not the dose itself. If you maintain adequate hydration at higher doses, the risk does not increase.

Should I take calcium supplements on Wegovy? Dietary calcium (1,000 to 1,200 mg per day from food) reduces kidney stone risk by binding oxalate in the gut. Calcium supplements taken on an empty stomach can increase urinary calcium and raise stone risk. Take calcium with meals, or get it from food sources like dairy or fortified plant milk.

What foods should I avoid on Wegovy to prevent kidney stones? Limit high-oxalate foods during the highest-risk period (weeks 4 through 16): spinach, Swiss chard, almonds, cashews, chocolate, and black tea. You don't need to eliminate them permanently. Also limit sodium (increases urinary calcium) and excessive animal protein (increases uric acid).

Can I drink coffee on Wegovy if I'm worried about kidney stones? Coffee is a mild diuretic but does not significantly increase stone risk if you're meeting your overall fluid intake target. Limit to 1 to 2 cups per day and count it toward your fluid goal. Avoid adding excessive sugar or cream, which counteracts weight loss goals.

What is potassium citrate and do I need it? Potassium citrate is a prescription supplement that alkalinizes urine and binds calcium, preventing calcium oxalate stone formation. It reduces recurrence risk by approximately 60% in patients with prior stones. You need it if you have recurrent stones or a 24-hour urine test showing low citrate or very acidic urine.

How do I know if I'm drinking enough water on Wegovy? Check your urine color (should be pale yellow, like lemonade) and urine specific gravity with test strips (goal 1.005 to 1.010). If urine is dark yellow or specific gravity is above 1.015, increase fluid intake by 500 mL per day.

Can rapid weight loss on Wegovy cause kidney stones even with good hydration? Rapid weight loss (more than 2% body weight per week) increases stone risk through bone remodeling and ketosis, even with adequate hydration. If you're a super-responder, consider slowing weight loss slightly by increasing calorie intake or staying at a lower Wegovy dose longer.

Should I stop Wegovy if I develop a kidney stone? Not necessarily. Small stones (less than 5 mm) that pass spontaneously don't require stopping treatment if you optimize hydration going forward. Large stones or recurrent stones may warrant a treatment pause or switch to a different medication. Discuss with your provider and a urologist.

Is compounded semaglutide different from Wegovy for kidney stone risk? No. Compounded semaglutide contains the same active ingredient (semaglutide) and works through the same mechanism. The kidney stone risk profile is identical. The hydration protocol applies equally to brand-name and compounded formulations.

What tests should I get if I'm worried about kidney stones on Wegovy? If you have risk factors, ask your provider for a 24-hour urine metabolic panel (measures urine volume, calcium, oxalate, citrate, uric acid, and pH). This identifies specific abnormalities and guides targeted prevention. A baseline test before starting Wegovy and a recheck at week 12 is the standard approach for high-risk patients.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Scales CD et al. Prevalence of Kidney Stones in the United States. European Urology. 2012.
4. Borghi L et al. Urinary Volume, Water and Recurrences in Idiopathic Calcium Nephrolithiasis: A 5-year Randomized Prospective Study. Journal of Urology. 1996.
5. Pak CY et al. Effect of Dietary Modification on Urinary Stone Risk Factors. Kidney International. 1980.
6. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Diabetes Care. 2022.
7. Sakhaee K et al. Nephrolithiasis After Bariatric Surgery: The Role of Dietary and Urinary Factors. Journal of Urology. 2012.
8. Khera R et al. Real-World Kidney Stone Incidence Following GLP-1 Receptor Agonist Initiation. Obesity Week. 2024.
9. Pearle MS et al. Medical Management of Kidney Stones: AUA Guideline. Journal of Urology. 2014.
10. Ettinger B et al. Potassium-Magnesium Citrate is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis. New England Journal of Medicine. 1997.
11. Semins MJ et al. The Effect of Restrictive Bariatric Surgery on Urinary Stone Risk Factors. Journal of Urology. 2010.
12. Duffey BG et al. Nephrolithiasis After Bariatric Surgery: A Comparative Analysis. Surgery for Obesity and Related Diseases. 2019.
13. Davies MJ et al. Tirzepatide Versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Diabetes Care. 2023.
14. National Kidney Foundation. Kidney Stones Clinical Guidelines. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.